Bausch Health Companies (NYSE:BHC) Stock Rating Reaffirmed by Royal Bank of Canada

Bausch Health Companies (NYSE:BHC - Get Free Report)'s stock had its "sector perform" rating reiterated by research analysts at Royal Bank of Canada in a research note issued to investors on Friday, Benzinga reports. They presently have a $12.00 price target on the stock. Royal Bank of Canada's price target suggests a potential upside of 37.06% from the company's current price.

Other equities research analysts have also issued reports about the company. StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Wednesday, February 7th. Jefferies Financial Group decreased their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, February 20th.

Bausch Health Companies Stock Down 2.4 %

Shares of Bausch Health Companies stock traded down $0.21 during trading on Friday, hitting $8.76. The stock had a trading volume of 5,242,672 shares, compared to its average volume of 2,805,503. The company has a market capitalization of $3.20 billion, a PE ratio of -5.33 and a beta of 0.85. Bausch Health Companies has a 1 year low of $5.57 and a 1 year high of $11.46. The stock has a 50 day simple moving average of $9.21 and a 200 day simple moving average of $8.13.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.14. The company had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The company's revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.02 EPS. As a group, equities analysts expect that Bausch Health Companies will post 3.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BHC. Salem Investment Counselors Inc. purchased a new stake in shares of Bausch Health Companies during the 1st quarter worth about $32,000. Principal Securities Inc. bought a new position in Bausch Health Companies during the fourth quarter valued at approximately $31,000. Lazard Asset Management LLC acquired a new stake in Bausch Health Companies in the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC grew its position in Bausch Health Companies by 283.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company's stock worth $55,000 after acquiring an additional 5,112 shares in the last quarter. Finally, Bfsg LLC acquired a new position in shares of Bausch Health Companies during the 4th quarter worth $63,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.